drugset / Trial / NCT03437590
A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to measure the blocking of \[18F\]-JNJ-64413739 uptake in the brain at the time to reach maximum plasma concentration (Tmax) and at 24 hours postdose of JNJ-55308942 following a single dose of JNJ-55308942; and to model the exposure/receptor interaction of JNJ-55308942.
Timeline
- Start
- 2018-03-15
- Primary completion
- 2018-10-19
- Completion
- 2018-10-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-JNJ-64413739 | Diagnostic / imaging agent | — | Intravenous |
| Subject | ZANVIPIXANT | Small molecule | 120 mg | Oral |
Indications
No indication recorded.